Vancomycin AUC Estimation When the Trough Looks High
A 58-year-old man weighing 110 kg and 170 cm tall is admitted with MRSA bacteremia. His serum creatinine is 1.8 mg/dL, and his estimated creatinine clearance is about 70 mL/min. The infectious diseases team orders vancomycin 1.5 g IV every 12 hours, infused over 1 hour. At steady state, the pharmacy draws a peak of 34 mg/L one hour after the end of the infusion and a trough of 17 mg/L 30 minutes before the next dose. The patient also receives piperacillin-tazobactam 4.5 g IV every 6 hours, furosemide 40 mg IV daily, and norepinephrine for blood pressure support. His urine output has decreased from 60 mL/h to 25 mL/h over the past 8 hours. The prescriber asks whether the vancomycin dose should be increased because the peak is only 34 mg/L and the MIC is 1 mg/L. The pharmacy has no Bayesian dosing software; you must estimate the AUC24 from the two levels.
1. Estimate the AUC24 from the two vancomycin levels. Show your reasoning.
Read the worked answer
Assume first-order elimination and use the two measured concentrations. The peak is drawn 1 hour after the end of the infusion, and the trough 30 minutes before the next dose, giving an interval of about 9 hours between the peak and trough.
Elimination rate constant: k = ln(Cpeak ÷ Ctrough) ÷ Δt = ln(34 ÷ 17) ÷ 9 h = ln(2) ÷ 9 h = 0.693 ÷ 9 h ≈ 0.077 h⁻¹
Half-life ≈ 0.693 ÷ 0.077 ≈ 9 hours.
For a 12-hour dosing interval, AUC12 can be estimated as: AUC12 = (Cpeak − Ctrough) ÷ k = (34 − 17) ÷ 0.077 ≈ 221 mg·h/L
Therefore: AUC24 ≈ 2 × 221 = 442 mg·h/L.
This is a simplified first-order estimate; exact sampling times, infusion duration, and assay timing matter. Still, the result is close enough to guide the decision: the AUC24 is approximately 440 mg·h/L, within the usual MRSA target of 400–600 mg·h/L.
2. Should the dose be increased because the peak is 34 mg/L and the MIC is 1 mg/L?
Read the worked answer
No. The peak concentration is not the preferred efficacy target for vancomycin. The relevant exposure measure for serious MRSA infection is the AUC24/MIC ratio, commonly targeted at 400–600 mg·h/L when the MIC is 1 mg/L. Here, the estimated AUC24/MIC is approximately 442/1 = 442, which is within target.
Increasing the dose because the peak is 'only' 34 mg/L would likely push the AUC above 600 mg·h/L and increase the risk of nephrotoxicity, especially in a patient with declining urine output. The trough of 17 mg/L is above the old traditional threshold of 15 mg/L, but troughs are a surrogate for AUC and should not be treated as the sole target. A high trough with an acceptable AUC does not require escalation.
The better response is to continue the current dose while monitoring renal function and clinical response, ensuring source control, and repeating levels if renal function changes. If the patient is not improving, evaluate the source, the organism, and the entire antibiotic regimen rather than reflexively increasing vancomycin.
3. What monitoring and adjustments are needed given the falling urine output and piperacillin-tazobactam?
Read the worked answer
The falling urine output from 60 mL/h to 25 mL/h is concerning for developing acute kidney injury. Vancomycin exposure will rise if renal clearance falls, so the current AUC estimate may not remain valid.
Monitor and act as follows:
- Check serum creatinine and urine output at least daily, and more often if renal function is changing. Track trends rather than a single value.
- Reassess the vancomycin dose if CrCl falls. A rising SCr may require extending the interval or reducing the dose, guided by repeat levels and AUC estimation.
- Recognize the vancomycin plus piperacillin-tazobactam association with AKI. If clinically feasible, the team should consider whether piperacillin-tazobactam is still necessary or whether an alternative is appropriate; do not stop it solely for this interaction without infectious diseases input.
- Monitor for infusion reactions and ensure the 1.5 g dose is infused over the ordered duration; rapid infusion can cause histamine-mediated flushing.
- Repeat blood cultures and assess source control. Persistent bacteremia may require longer therapy and source drainage, not just higher vancomycin levels.
Document the AUC calculation, the recommendation to continue rather than escalate, and the monitoring plan.